NASDAQ · NRXP
NRX Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NRXP: Nov 13, 2026
NRX Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.29. The reported EPS for the same quarter last year was $-0.18.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.29 | $-0.15 | $-0.43 | 2 |
| Dec 2026 | $-0.34 | $-0.17 | $-0.50 | 2 |
| Mar 2027 | $-0.24 | $-0.17 | $-0.30 | 2 |
| Jun 2027 | $-0.14 | $-0.13 | $-0.15 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat- RTTNews · Oct 30, 7:41 AM EDTNRx Pharmaceuticals Secures FDA Nod For Preservative-Free Ketamine Ahead Of Target Date; Stock Up(RTTNews) – NRx Pharmaceuticals, Inc. (NRXP) announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine, ahead of the agency's November 10 approval goal date.
- Zacks · Oct 29, 6:10 AM EDTShionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag EstimatesShionogi & Co. (SGIOY) delivered earnings and revenue surprises of -38.46% and +5.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- RTTNews · Oct 15, 12:19 PM EDTNRx Pharmaceuticals Targets November FDA Deadline For Preservative-Free Ketamine(RTTNews) – NRx Pharmaceuticals Inc. (NRXP) announced Thursday that it has received a Discipline Review Letter from the U.S. Food and Drug Administration (FDA) requesting minor changes to the labeling of its preservative-free ketamine product.
- RTTNews · Oct 15, 9:01 AM EDTNRx Pharmaceuticals Receives FDA Label Revision Request For Its Preservative-Free Ketamine Product(RTTNews) – Thursday, NRx Pharmaceuticals, Inc. (NRXP) announced that the U.S. Food and Drug Administration has requested minor changes to the submitted label for NRx's Preservative-Free Ketamine product.
- Zacks · Sep 24, 7:00 AM EDTOno Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- RTTNews · Sep 16, 1:32 AM EDTNRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As Minor(RTTNews) – NRx Pharmaceuticals, Inc. (NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. FDA has reclassified an amendment to its Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free intravenous ketamine formulation, from a Major Amend
- RTTNews · Sep 14, 9:23 AM EDTGeNeuro Secures European Patent For GNK-301 In ALS(RTTNews) – NRx Pharmaceuticals (NRXP) announced that its subsidiary GeNeuro, Inc. has been awarded European Patent EP 3 570 878 B1 covering GNK-301, a novel monoclonal antibody targeting the envelope protein of Human Endogenous Retrovirus K (HERV K) for the potential treatment o
- RTTNews · Aug 17, 9:08 AM EDTNRx's Half -Yearly Loss Narrows; ANDA Response For NRX-100 In '27(RTTNews) – NRx Pharmaceuticals Inc. (NRXP), a clinical-stage biopharmaceutical company, on Monday announced financial results for the first half year and second quarter of 2026, noting a lower net loss owing to certain air-value accounting measures and a convertible notes conver
- Zacks · Aug 14, 8:15 PM EDTNRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue EstimatesNRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Aug 10, 10:04 AM EDTNRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles5 Biotech stocks tapping into unmet mental health treatment needsNRx Pharmaceuticals (NASDAQ:NRXP) said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining i
- RTTNews · Aug 7, 8:51 AM EDTNRXP: FDA Clears First-Cycle Review Of Preservation-Free Ketamine ANDA; Approval Awaits Vial Cert(RTTNews) – NRx Pharmaceuticals, Inc. (NRXP) reported that the U.S. FDA has completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine, finding no major deficiencies in the drug product, labeling, or manufacturing cont
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for NRX Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.